Purchase Deltasone (Prednisone) tablets online
How and where to order Prednisone 5 mg, 10 mg, 20 mg, 40 mg tablets or capsules online:
Shop: DFH PHARMACY
Stores: PHARMA DOCTOR
from $0.26 per pill
10% coupon: DFHDCC
Prednisone 5 mg, 10 mg, 20 mg, 40 mg tablets
Prednisone brand, Deltasone generic
PayPal, Visa, Mastercard, AmEx, Bitcoin
Standard airmail and trackable courier service
Worldwide, including USA, UK, Europe, Canada, Australia
(trade names include Deltasone, Apo-Prednisone, Cortancyl, Dacortin, Prednison Hexal, Decortin, Prednisona Cinfa Laboratorios, Deltacortene, Encorton, Prednisone Arrow Generiques, Lodotra, Meticorten, Novo-Prednisone, Orasone, Prednisone Mylan, Panafcort, Prednisone Roxane Laboratories, Predni Tablinen, Prednisone Sandoz, Pulmison, Rectodelt, Teva-Prednisone
) is a glucocorticosteroid (glucocorticoid, GCS) medication for local and systemic use. This medicine is indicated for the treatment of various diseases and medical conditions such as severe allergic reactions (including allergic rhinitis, allergic conjunctivitis, skin rash), certain types of arthritis (like gouty arthritis, rheumatoid arthritis, giant-cell arteritis, rheumatologic diseases, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis); rheumatic disorders, inflammatory conditions, chronic inflammatory demyelinating polyneuropathy (CIDP), bursitis, tennis elbow (lateral epicondylitis), erythroblastopenia, thrombocytopenia, idiopathic thrombocytopenic purpura, syphilis, herpes zoster, herpes zoster iridocyclitis, shingles, immunosuppression (for example to prevent rejection after organ transplant), pericarditis, decompensated heart failure, uveitis, posterior uveitis, keratitis, corneal ulcer, synovitis, lupus, systemic lupus erythematosus, scleroderma, eczema, severe psoriasis, dermatitis herpetiformis, atopic dermatitis, dermatomyositis, seborrheic dermatitis, toxic epidermal necrolysis, poison oak exposure, polymyositis, mycosis fungoides, mixed connective tissue disease, ankylosing spondylitis, severe asthma, chronic obstructive pulmonary disease (COPD), aspiration pneumonia, lipid pneumonitis, migraine headaches, cluster headaches, fibromyalgia, nephrotic syndrome, neurosarcoidosis, sarcoidosis, endocrine (hormonal) disorders, ulcerative colitis, severe aphthous ulcer, inflammatory bowel disease, berylliosis, chorioretinitis, iritis, iridocyclitis, Crohn's disease, Cogan's syndrome, Loeffler's syndrome, Meniere's disease, Herxheimer reaction, Duchenne muscular dystrophy, Ramsay hunt syndrome, Graft-versus-host disease, granulomatosis with polyangiitis, lichen planus, lichen sclerosus, multiple sclerosis, systemic sclerosis, myasthenia gravis, pemphigoid, bullous pemphigoid, pemphigus, autoimmune hemolytic anemia, autoimmune hepatitis, other autoimmune diseases, thyroiditis, laryngitis, pharyngitis, sinusitis, urticaria (hives), tuberculous meningitis, severe tuberculosis, extrapulmonary tuberculosis, hypercalcemia (high blood calcium) due to cancer, adrenal insufficiency, adrenocortical insufficiency, adrenogenital syndrome; allergic disorders, and other conditions that affect skin, lungs, eyes, thyroid, kidneys blood, stomach and intestines. Sometimes it is used as antitumor drug to treat symptoms of certain types of cancer such as acute lymphocytic leukemia (acute lymphoblastic leukemia), diffuse large B-cell lymphoma, non-Hodgkin lymphomas, Hodgkin's lymphoma, multiple myeloma, hypercalcemia of malignancy, other hormone-sensitive tumors, in combination with other anticancer drugs. Prednisone is wiledly used in veterinary for dogs, cats, other pets and animals. This medication works by decreasing or preventing tissues from responding to inflammation. It also modifies the body's response to certain immune stimulation.
Mefenamic Acid (Ponstel)
Pharmacological and medical categories:
Anti inflammatory agents
Anti cancer drugs
Antihistamines and antiallergics
Topical corticosteroids for the treatment of dermatological diseases
Veterinary, pet meds
A - Alimentary tract and metabolism
A07 - Antidiarrheals, intestinal antiinflammatory/antiinfective agents
A07E - Intestinal antiinflammatory agents
A07EA - Corticosteroids acting locally
A07EA03 - Prednisone
H - Systemic hormonal preparations, excl. sex hormones and insulins
H02 - Corticosteroids for systemic use
H02A - Corticosteroids for systemic use, plain
H02AB - Glucocorticoids
H02AB07 - Prednisone
Respiratory tuberculosis - A15
Tuberculosis of nervous system - A17
Tuberculous meningitis - A17.0
Infections with a predominantly sexual mode of transmission - A50-A64
Other and unspecified syphilis - A53
Zoster [herpes zoster] - B02
Postherpetic geniculate ganglionitis - B02.21
Zoster iridocyclitis - B02.32
Zoster without complications - B02.9
Candidiasis - B37
Neoplasms - C00-D48
Hodgkin lymphoma - C81
Non-follicular lymphoma - C83
Diffuse large B-cell lymphoma - C83.3
Mature T/NK-cell lymphomas - C84
Mycosis fungoides - C84.0
Other specified and unspecified types of non-Hodgkin lymphoma - C85
Multiple myeloma and malignant plasma cell neoplasms - C90
Lymphoid leukemia - C91
Acquired hemolytic anemia - D59
Acquired pure red cell aplasia [erythroblastopenia] - D60
Purpura and other hemorrhagic conditions - D69
Immune thrombocytopenic purpura - D69.3
Thrombocytopenia, unspecified - D69.6
Other disorders of white blood cells - D72
Eosinophilia - D72.1
Certain disorders involving the immune mechanism - D80-D89
Sarcoidosis - D86
Other disorders involving the immune mechanism, not elsewhere classified - D89
Graft-versus-host disease - D89.81
Endocrine, nutritional and metabolic diseases - E00-E89
Thyroiditis - E06
Adrenogenital disorders - E25
Other disorders of adrenal gland - E27
Primary adrenocortical insufficiency - E27.1
Disorders of mineral metabolism - E83
Hypercalcemia - E83.52
Multiple sclerosis - G35
Migraine - G43
Other headache syndromes - G44
Cluster headaches and other trigeminal autonomic cephalgias (TAC) - G44.0
Inflammatory polyneuropathy - G61
Chronic inflammatory demyelinating polyneuritis - G61.81
Myasthenia gravis and other myoneural disorders - G70
Primary disorders of muscles - G71-
Muscular dystrophy - G71.0
Conjunctivitis - H10
Other chronic allergic conjunctivitis - H10.45
Keratitis - H16
Corneal ulcer - H16.0
Diffuse interstitial keratitis, unspecified eye - H16.329
Iridocyclitis - H20
Unspecified acute and subacute iridocyclitis - H20.00
Chorioretinal inflammation - H30
Disorders of vestibular function - H81
Meniere's disease, unspecified ear - H81.09
Acute pericarditis - I30
Heart failure - I50
Haemorrhoids - I84
Acute sinusitis - J01
Acute pharyngitis - J02
Acute laryngitis and tracheitis - J04
Vasomotor and allergic rhinitis - J30
Other chronic obstructive pulmonary disease - J44
Asthma - J45
Pneumoconiosis due to other inorganic dusts - J63
Berylliosis - J63.2
Pneumonitis due to solids and liquids - J69
Pneumonitis due to inhalation of food and vomit - J69.0
Pneumonitis due to inhalation of oils and essences - J69.1
Stomatitis and related lesions - K12
Recurrent oral aphthae - K12.0
Crohn's disease [regional enteritis] - K50
Ulcerative colitis - K51
Fissure and fistula of anal and rectal regions - K60
Other inflammatory liver diseases - K75
Autoimmune hepatitis - K75.4
Pemphigus - L10
Pemphigoid - L12
Bullous pemphigoid - L12.0
Other bullous disorders - L13
Dermatitis herpetiformis - L13.0
Dermatitis and eczema - L20-L30
Atopic dermatitis - L20
Seborrheic dermatitis - L21
Allergic contact dermatitis - L23
Allergic contact dermatitis due to plants, except food - L23.7
Irritant contact dermatitis - L24
Pruritus - L29
Other dermatitis - L30
Psoriasis - L40
Psoriatic arthritis mutilans - L40.52
Lichen planus - L43
Urticaria - L50
Erythema multiforme - L51
Toxic epidermal necrolysis [Lyell] - L51.2
Atrophic disorders of skin - L90
Lichen sclerosus et atrophicus - L90.0
Rheumatoid arthritis with rheumatoid factor - M05
Other rheumatoid arthritis - M06
Gout - M10
Osteoarthritis - M15-M19
Systemic connective tissue disorders - M30-M36
Other necrotizing vasculopathies - M31
Other giant cell arteritis - M31.6
Systemic lupus erythematosus (SLE) - M32
Dermatopolymyositis - M33
Polymyositis - M33.2
Systemic sclerosis [scleroderma] - M34
Other systemic involvement of connective tissue - M35
Systemic involvement of connective tissue, unspecified - M35.9
Ankylosing spondylitis - M45
Synovitis and tenosynovitis - M65
Soft tissue disorders related to use, overuse and pressure - M70
Other bursopathies - M71
Bursopathy, unspecified - M71.9
Other enthesopathies M77
Lateral epicondylitis - M77.1
Other and unspecified soft tissue disorders, not elsewhere classified - M79
Rheumatism, unspecified - M79.0
Fibromyalgia - M79.7
Nephrotic syndrome - N04
Other inflammation of vagina and vulva - N76
Rash and other nonspecific skin eruption - R21
Other general symptoms and signs - R68
Herxheimer's reaction - R68.89
Adverse effects, not elsewhere classified - T78
Need for other prophylactic measures - Z29
Personal history of medical treatment - Z92
Personal history of immunosupression therapy - Z92.25
Indications and usage:
Prednisone tablets is a corticosteroid indicated:
as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervoussystem, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation
for the treatment of certain endocrine conditions
for palliation of certain neoplastic conditions
Dosage and administration:
Individualize dosing based on disease severity and patient response. The timing of administration should take into account the delayed-release pharmacokinetics and the disease or condition being treated:
Initial dose: prednisone 5 mg administered once per day. Patients currently on immediate-release prednisone, prednisolone, or methylprednisolone should be switched to prednisone at an equivalent dose based on relative potency.
Maintenance dose: use lowest dosage that will maintain an adequate clinical response.
Discontinuation: withdraw gradually if discontinuing long-term or high-dose therapy.
Prednisone should be taken daily with food.
This medication should be swallowed whole and not broken, divided, or chewed.
The effects of accidental ingestion of large quantities of prednisone over a very short period of time have not been reported, but prolonged use of the drug can produce mental symptoms, moon face, abnormal fat deposits, fluid retention, excessive appetite, weight gain, hypertrichosis, acne, striae, ecchymosis, increased sweating, pigmentation, dry scaly skin, thinning scalp hair, increased blood pressure, tachycardia, thrombophlebitis, decreased resistance to infection, negative nitrogen balance with delayed bone and wound healing, headache, weakness, menstrual disorders, accentuated menopausal symptoms, neuropathy, fractures, osteoporosis, peptic ulcer, decreased glucose tolerance, hypokalemia, and adrenal insufficiency.Hepatomegaly and abdominal distention have been observed in children.
Treatment of acute overdosage is by immediate gastric lavage or emesis followed by supportive and symptomatic therapy. For chronic overdosage in the face of severe disease requiring continuous steroid therapy the dosage of prednisone may be reduced only temporarily, or alternate day treatment may be introduced.
Dosage forms and strengths:
Prednisone tablets 1 mg, 2 mg, 5 mg, 10 mg, 20 mg, 40 mg.
Known hypersensitivity to prednisone or any excipients in the formulation.
Warnings and precautions:
Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and hyperglycemia: monitor patients for these conditions with chronic use. Taper doses gradually for withdrawal after chronic use.
Infections: increased susceptibility to new infection and increased risk of exacerbation, dissemination, or reactivation of latent infection. Signs and symptoms of infection may be masked.
Elevated blood pressure, salt and water retention, and hypokalemia: monitor blood pressure and sodium, potassium serum levels.
GI perforation: increased risk in patients with certain GI disorders. Signs and symptoms may be masked.
Behavioral and mood disturbances: may include euphoria, insomnia, mood swings, personality changes, severe depression, and psychosis. Existing conditions may be aggravated.
Decreases in bone density: monitor bone density in patients receiving long term corticosteroid therapy.
Ophthalmic effects: may include cataracts, infections, and glaucoma. Monitor intraocular pressure if corticosteroid therapy is continued for more than 6 weeks.
Live or live attenuated vaccines: do not administer to patients receiving immunosuppressive doses of corticosteroids.
Negative effects on growth and development: monitor pediatric patients on long-term corticosteroid therapy.
Embryo-Fetal toxicity: can cause fetal harm with first trimester use. Advise patientsofpotential harm to the fetus.
Adverse reactions, side effects:
Common adverse reactions for prednisone and other corticosteroids include fluid retention, alteration in glucose tolerance, elevation in bl ood pressure, behavioraland mood changes, increased appetite and weight gain.
To report suspected side effects of prednisone contact your local FDA.
Anticoagulant agents: prednisone may enhance or diminish anticoagulant effects.
Antidiabetic agents: may increase blood glucose concentrations. Dose adjustments of antidiabetic agents may be required.
CYP 3A4 inducers and inhibitors: may, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment.
Cyclosporine: increase in activity of both, cyclosporine and corticosteroid when administered concurrently. Convulsions have been reported with concurrent use.
NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects.
Patient counseling information:
Patients should be informed of the following information before initiating therapy with prednisone and periodically during the course of ongoing therapy.
Patients should be warned not to discontinue the use of prednisone abruptly or without medical supervision, to advise any medical attendants that they are taking it, and to seek medical advice at once should they develop fever or other signs of infection. Patients should be told to take prednisone exactly as prescribed, followthe instructions on the prescription label, and not stop taking this medication without first checking with their healthcare providers, as there may be a need for gradual dose reduction.
Patients should discuss with their physician if they have had recent or ongoing infections or if they have recently received a vaccine.
Persons who are on immunosuppressant doses of corticosteroidsshould be warned to avoid exposure to chickenpox or measles. Patients should also be advised that if they are exposed, medical advice should be sought without delay.
There are a number of medicines that can interact with prednisone. Patients should inform their healthcare provider of all the medicines they are taking, including over-the-counter and prescription medicines (such as phenytoin, diuretics, digitalis or digoxin, rifampin, amphotericin B, cyclosporine, insulin or diabetes medicines, ketoconazole, estrogens including birth control pills and hormone replacement therapy, blood thinners such as warfarin, aspirin or other NSAIDS, barbiturates), dietary supplements, and herbal products. If patients are taking any of these drugs, alternate therapy, dosage adjustment, and/or special test may be needed during the treatment.
For missed doses, patients should be told to take the missed dose as soon as they remember. If it is almost time for the next dose, the missed dose should be skipped and the medicine taken at thenext regularly schedule time. Patients should not take an extra dose to make up for the missed dose.
Patients should be told to take prednisone with food. Patients should be advised not to break, divide, or chew this medicine.
Patients should be advised of common adverse reactions that could occur with prednisone use to include fluid retention, alteration in glucose tolerance, elevation in blood pressure, behavioral and mood changes, increased appetite and weight gain.
Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy.
A - Australia
C - United States (Risk cannot be ruled out)
D - United States (Positive evidence of risk) for delayed-release tablets
Salts and other forms:
Synonyms, international and chemical names:
Brands, generics, trade names:
Apo-Prednisone - Apotex, Nhan Tam, Pharmaforte
Artinizona - Teuto-Brasileiro Laboratorio
Cortancyl - Sanofi-Aventis
Corticorten - Neo Quimica Comercio e Industria Laboratorio
Cortiprex - Chile Laboratorios
Dacortin - Merck
Decortin - Merck
Dekortin - Merck
Deltacortene - Bruno Farmaceutici
Deltasone - Pfizer
Deltison - Recipharm
Encorton - Polfa Pabianice
Hostacortin - Sanofi-Aventis
Lodotra - Mundipharma
Meticorten - Bayer Schering Pharma, Essex, Schering-Plough
Nisona - Unidos Laboratorios
Nosipren - Collins Productos Farmaceuticos
Novo-Prednisone - Novopharm
Orasone - Solvay
Panafcort - Aspen
Pred - Prosel Pharma
Predni Tablinen - Hexal, Lichtenstein Pharmazeutica
Prednison - Acis Arzneimittelvertrieb, G. Streuli, Hexal, Ratiopharm, Sandoz
Prednisona - Cinfa Laboratorios, Kern Pharma, Rider Laboratorios, Sanofi-Aventis
Prednisone - Arrow Generiques, Biogaran, EG Labo, Mylan, Organon, Roxane Laboratories, Sandoz, Teva
Prednisone Intensol - Roxane Laboratories
Pronison - Galenika
Pulmison - Boehringer Ingelheim
Rayos - Horizon Therapeutics
Rectodelt - Trommsdorff Arzneimittel, Afamia Trade, R-Mark
Sterapred - Merz
Ultracorten - Novartis
APIs used in medicine in combinations with prednisone:
Here is a list of popular medications containing prednisone as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:
|Trade name of the drug
||Pharmaceutical forms and doses
||Tablets; Oral; Prednisone 2.5 mgTablets; Oral; Prednisone 5 mgTablets; Oral; Prednisone 10 mgTablets; Oral; Prednisone 20 mgTablets; Oral; Prednisone 50 mg
||Tablets, Prolonged Release; Oral; Prednisone 1 mgTablets, Prolonged Release; Oral; Prednisone 2 mgTablets, Prolonged Release; Oral; Prednisone 5 mg
||MundipharmaAenova GroupHorizon Pharma
||Tablets; Oral; Prednisone 1 mgTablets; Oral; Prednisone 5 mgTablets; Oral; Prednisone 10 mgTablets; Oral; Prednisone 20 mgTablets; Oral; Prednisone 50 mg
||Tablets; Oral; Prednisone 1 mgTablets; Oral; Prednisone 5 mgTablets; Oral; Prednisone 25 mg
||Tablets; Oral; Prednisone 5 mgTablets; Oral; Prednisone 10 mgTablets; Oral; Prednisone 20 mg
Prednisone main article on Wikipedia: https://en.wikipedia.org/wiki/Prednisone
Prednisone compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone
Prednisone medicine on DrugBank: https://go.drugbank.com/drugs/DB00635
Prednisone FAQ on MedlinePlus (revised 03/15/2020): https://medlineplus.gov/druginfo/meds/a601102.html
Deltasone (Prednisone) tablets drug label on DailyMed (revised November 2, 2018): https://dailymed.nlm.nih.gov/dailymed/lookup...
Prednisone tablets drug label on DailyMed (revised December 17, 2019): https://dailymed.nlm.nih.gov/dailymed/drugInfo...
Prednisone for sale on Pharma Doctor (revised October 2021): https://pharma-doctor.com/prednisone.html
Prednisone containing drugs on Drugs-About.com: https://drugs-about.com/ing/prednisone.html
Rayos (Prednisone) delayed-release tablets 1 mg, 2 mg, 5 mg official prescribing information from the U.S. FDA (revised July 2012): https://www.accessdata.fda.gov/drugsatfda_docs/label...
Deltasone (Prednisone) tablets prescribing information from Drugs.com (revised August 2006): https://www.drugs.com/pro/deltasone.html
Lodotra (Prednisone) 1 mg, 2 mg and 5 mg modified release tablets product information from GP2U TeleHealth (revised 7 August 2012): https://gp2u.com.au/static/pdf/L/LODOTRA-PI.pdf
Panafcort (Prednisone) tablets product information from The Therapeutic Goods Administration (revised 19 April 2021): https://www.ebs.tga.gov.au/ebs/picmi/...
Prednisone (Deltasone) patient fact sheet from American College of Rheumatology: https://www.rheumatology.org/Portals/0/Files/...
Revised: October 2021